India Globalization Capital Provides Update on Hyalolex for Alzheimer’s Commercialization Strategy
December 14 2017 - 8:00AM
India Globalization Capital, Inc. (NYSE American:IGC) today
provides an update on corporate initiatives to launch its lead
product for Alzheimer’s, Hyalolex, through licensed medical
dispensaries in the U.S. Investors and interested parties are
encouraged to visit www.Hyalolex.com for information on Alzheimer’s
disease and research data related to our product formulation.
Hyalolex Liquid Formulation
As previously reported, IGC has a two-part strategy for
commercializing its lead product, Hyalolex. It is
anticipated, subject to adequate funding, to move the Alzheimer’s
formulation through FDA registered pre-clinical and clinical
trials. Independent of the FDA process, IGC expects to
license its formulation technology for distribution as a
Complimentary and Alternative Medicine (CAM) through licensed
medical cannabis dispensaries in key markets of the U.S. This
process will include state-by-state sourcing, formula assembly,
packaging and distribution utilizing best practices to ensure
quality control while complying with the current legal guidelines
established by each individual state in which Hyalolex is
sold. Medical cannabis is currently legal in 29 states and in
Washington, D.C.
Early 2018 Initial Rollout / Marketing
Program
IGC has identified dispensaries in Washington, D.C. and Maryland
as initial distribution sites to launch the product once final
inventory is secured. This is expected to occur in early 2018
with subsequent expansion into additional U.S. states dependent on
product procurement and associated compliance achievement. In
anticipation of this, IGC has retained The Medical Marketing Group,
Inc., a provider of outsourced product-detailing, education and
outreach services to assist with the Company’s national dispensary
expansion ambitions.
Alzheimer’s patients suffer from a host of symptoms including
anxiety, agitation, and sleep disorders. The hallmarks of
Alzheimer’s include plaques, tangles, and dementia. Hyalolex has
been shown to decrease plaques and tangles, control anxiety, and
help with sleep disorders thorough a patent-pending pathway.
Based on these and other studies, we expect to bring Hyalolex to
market in early 2018, with the hope of bringing much needed relief
to Alzheimer’s patients.
About IGC
The Company has two lines of businesses: a legacy infrastructure
business and a cannabis pharmaceutical business that has developed
a lead product for treating Alzheimer’s patients. It is also
engaged in the development of cannabis based combination therapies
to treat pain, nausea, eating disorders, several endpoints of
Parkinson’s, and epilepsy in dogs and cats. The company is
based in Maryland, USA.
For more information please visit www.igcinc.us Follow us on
Twitter @IGCIR and Facebook.com/IGCIR/
Forward-looking Statements
Please see forward-looking statements and risk factors as
discussed in detail in IGC's Form 10K for fiscal year ended March
31, 2017, and in other reports filed with the U.S. Securities and
Exchange Commission.
ContactClaudia Grimaldi301-983-0998